Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
FQ-42 Vengeance Finds New Home at Creech Air Force Base21.9.2026 17:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / September 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) congratulates the U.S. Air Force (USAF) on the pace of progress for its Collaborative Combat Aircraft program, which features the FQ-42 Vengeance designed and produced by GA-ASI. The latest milestone took place Sept. 18, when a new FQ-42 Vengeance was delivered to Creech AFB, Nev., to continue operations with test and evaluation units. "The CCA program's rate of progress has been incredible," said Mike Atwood, GA-ASI Vice President of Advanced Programs. "Every week, the Air Force is pushing forward with new and more impressive accomplishments using Vengeance. It's amazing to think of how far this program has come in such a short amount of time." The FQ-42 that arrived at Creech will continue regular test and evaluation operations with the Air Force aimed at experimentation with the new aircraft. Previous efforts with Vengeance and other GA-ASI jets, including XQ-67A Off-Board Sens
Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine21.9.2026 15:45:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced Dream Bowl XV. The game is the 15th anniversary edition of the premier college football all-star showcase for professional draft-eligible talent from all college divisions and NAIA programs. It will be held Sunday, January 17, 2027, at AT&T Stadium in Arlington, Texas, and is planned to be broadcast nationally on ESPN. Dream Bowl XV continues Datavault AI's role as an intellectual property licensing partner and official sponsor of The Dream Bowl alongside Cutting-Edge Sports Management. It builds on the Company's debut at Dream Bowl XIV. Since 2013, The Dream Bowl has honored the legacy of Dr. Martin Luther King Jr. and has given overlooked collegiate athletes a professional-caliber send-off in front of professional scouts. N
Winners of this Year's Semmelweis-Richter International Journalism Award Announced21.9.2026 14:05:00 CEST | Press release
BUDAPEST I. KERÜLET, HU / ACCESS Newswire / September 21, 2026 / For the second time, Semmelweis University, with the support of Gedeon Richter, has recognized outstanding health and science journalism from across Europe through the Semmelweis-Richter Journalism Award. Six entries received awards in the "Women's Health" and "Pharmaceutical Strategies and Innovation" categories. The first prizes in the two categories were awarded to an international investigative project on abortion and an article about a technology that uses miniature bioengineered devices to mimic the functions of human organs. The competition received around 60 entries from nearly 20 countries. The Semmelweis-Richter Journalism Award was established to recognize high-quality health and science journalism in Europe. As last year, the competition attracted entries from journalists working for major international media outlets, including The Guardian, the Financial Times, The Times, BBC News, Süddeutsche Zeitung and Púb
NOVELIC Partners with Global DMS Leader Smart Eye to Develop Next-Generation Camera and Radar In-Cabin Monitoring Systems21.9.2026 08:00:00 CEST | Press release
BELGRADE, RS / ACCESS Newswire / September 21, 2026 / NOVELIC, a Belgrade-based innovator in mmWave radar solutions, announced a strategic partnership with Smart Eye, a global leader in Driver Monitoring Systems (DMS) and Interior Sensing AI, to provide OEMs with a well-rounded feature set that satisfies the upcoming Euro NCAP requirements for driver and occupant monitoring. The result is a scalable and cost-effective solution that combines vision and radar for straightforward integration. Since the software is running entirely on the sensor, only a single CAN-Bus interface to the vehicle is required, eliminating the need for external hardware, LVDS interfaces, and added computational load elsewhere in the car. NOVELIC and Smart Eye's innovative system approach will debut at Smart Eye's booth #305 at InCabin Europe 2026 in Barcelona. The demonstration will showcase enhanced performance and compliance with relevant safety protocols through the fusion of radar and vision technologies. NO
Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner17.9.2026 14:50:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / September 17, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ali Palmer as a Partner in the firm's Human Resources Practice. Based in London, Palmer advises boards, chief executive officers and chief people officers on the recruitment of senior human resources leaders, helping organizations build leadership teams that enable growth, transformation and long-term performance. Ali Palmer, Partner in Caldwell's Human Resources Practice. With more than 20 years of executive search and leadership advisory experience, Palmer partners with listed companies, private equity-backed businesses and privately held organizations across a broad range of sectors, with particular expertise in consumer, retail, industrial, financial services, pharmaceutical and technology. She leads executive search assignments across the full human resources function, from chief people officers and chief human resources
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom